Remove Diabetes Remove Pharmaceutical Manufacturing Remove White Paper
article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Eylea is approved in four indications in Europe: the treatment of ‘wet’ age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

article thumbnail

Bridging the gap: A comprehensive approach to social determinants of health

Pharmaceutical Technology

SDoH can influence diabetes risk and management, and access to healthcare can also affect disease management and progression. One study dove into whether annual income influenced choice in GLP-1 RA therapy for patients with Type 2 Diabetes. medication accessibility), especially in cases where there are multiple in-class agents.”

article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

Biologics and antibiotics could be worst hit due to their energy-intensive manufacturing processes, along with the supply of glass vials and syringes disrupting the supply chain. Moreover, US Pharmacopeia issued the first-ever Medicine Supply Map to find and quantify risks in upstream pharmaceutical supply chains across the country.